VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AGL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AGLAgilon Health, Inc.
$115.20$1.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksAGLFinancials

Agilon Health, Inc. (AGL) Income Statement

7Y historyFree accessUpdated daily

Revenue has remained near $1.4B to $1.6B while gross margin swung between roughly -6% and +7%, with the latest 1.6% operating margin suggesting a fragile recovery that warrants further investigation.

Income StatementBalance SheetCash FlowRatios

AGL Income Statement

Annual statement

AGL Income Statement

Agilon Health, Inc. (AGL) annual income statement — 7-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Sales/Revenue6B5.93B6.06B4.32B2.39B1.52B1.22B794.41M
Revenue Growth %2.02%-2.11%40.41%80.74%56.97%24.88%53.36%-
Cost of Goods Sold5.84B6.12B6.06B4.25B2.28B1.46B1.12B765.9M
COGS % of Revenue-103.18%99.92%98.39%95.34%95.68%92.27%96.41%
Gross Profit165.71M-188.61M4.84M69.67M111.36M65.74M94.15M28.51M
Gross Margin %2.76%-3.18%0.08%1.61%4.66%4.32%7.73%3.59%
Gross Profit Growth %--3996.2%-93.05%-37.44%69.38%-30.17%230.22%-
Operating Expenses275.48M232.46M296.97M301.8M216.74M437.99M150.82M135.09M
OpEx % of Revenue-3.92%4.9%6.99%9.08%28.79%12.38%17%
Selling, General & Admin269.97M238.54M268.91M285.76M207.79M427.5M137.29M122.83M
SG&A % of Revenue-4.02%4.44%6.62%8.7%28.1%11.27%15.46%
Research & Development00000000
R&D % of Revenue--------
Other Operating Expenses0-6.08M28.06M16.04M8.95M10.48M13.53M12.25M
Operating Income-109.77M-421.08M-292.13M-232.13M-105.38M-372.24M-56.67M-106.57M
Operating Margin %-1.83%-7.1%-4.82%-5.38%-4.41%-24.47%-4.65%-13.42%
Operating Income Growth %--44.14%-25.85%-120.29%71.69%-556.82%46.82%-
EBITDA-82.41M-392.48M-267.67M-211.97M-91.61M-357.57M-42.57M-65.16M
EBITDA Margin %-1.37%-6.62%-4.42%-4.91%-3.84%-23.5%-3.49%-8.2%
EBITDA Growth %76.41%-46.63%-26.27%-131.4%74.38%-739.88%34.66%-
D&A (Non-Cash Add-back)27.36M28.59M24.46M20.16M13.77M14.67M14.1M41.41M
EBIT-112.7M-397.45M-242.65M-187.8M-86.19M-376.83M-54.21M-105.62M
Net Interest Income-3.26M-6.64M-6.18M-6.66M-4.48M-6.15M-8.13M-9.07M
Interest Income00000000
Interest Expense3.26M6.64M6.18M6.66M4.48M6.15M8.13M9.07M
Other Income/Expense8.64M16.98M43.3M37.67M14.71M-10.73M-5.67M-8.11M
Pretax Income-101.12M-404.1M-248.83M-194.46M-90.67M-382.98M-62.34M-114.69M
Pretax Margin %-1.68%-6.81%-4.11%-4.51%-3.8%-25.17%-5.12%-14.44%
Income Tax4.92M1.25M1.45M791K1.64M886K865K-232K
Effective Tax Rate %-4.86%-0.31%-0.58%-0.41%-1.81%-0.23%-1.39%0.2%
Net Income-106.04M-405.35M-260.15M-262.6M-106.55M-406.49M-60.05M-282.59M
Net Margin %-1.77%-6.83%-4.29%-6.08%-4.46%-26.72%-4.93%-35.57%
Net Income Growth %65.6%-55.81%0.93%-146.45%73.79%-576.89%78.75%-
Net Income (Continuing)-106.04M-405.35M-250.28M-195.25M-92.31M-383.86M-63.21M-114.45M
Discontinued Operations00-9.82M-67.55M-14.55M-22.93M3.16M0
Minority Interest000-818K-611K-300K00
EPS (Diluted)-6.00-24.50-15.75-16.00-6.50-27.25-4.00-18.50
EPS Growth %64.32%-55.56%1.56%-146.15%76.15%-581.25%78.38%-
EPS (Basic)--24.50-15.75-16.00-6.50-27.25-4.00-18.50
Diluted Shares Outstanding17.69M16.56M16.44M16.36M16.33M14.92M15.39M15.36M
Basic Shares Outstanding16.79M16.56M16.44M16.36M16.33M14.92M15.39M15.36M
Dividend Payout Ratio--------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Persistent negative gross margins

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Stabilizing After Volatile Stretch

Based on AGL's reported quarterly figures, revenue has held near $1.4B to $1.6B across the ten quarters, with the latest quarter showing a 5.9% sequential-style growth signal that remains insufficient to confirm a durable reacceleration in the top line.

The revenue base has been essentially flat in absolute terms, suggesting membership growth is being offset by per-member economics or attrition. The year-over-year change of -2.1% points to contraction at the consolidated level, while the most recent quarter's uptick may reflect favorable seasonality or risk-adjustment timing rather than a structural shift. Investors should monitor whether membership and risk-adjusted revenue per member move in the same direction before treating this as a trend.

Gross Margin Recovery Remains Fragile

As reported in AGL's income statement, gross margin has swung between roughly -6% and +7% across recent quarters, with the most recent print of 6.4% suggesting improvement but not yet evidence of stable unit economics.

The move from deeply negative gross profit in late 2025 to positive territory in 2026 is directionally encouraging, yet the margin has been volatile enough that a single quarter should not be extrapolated. Medical cost ratios appear to be the dominant swing factor, and the gap between capitation revenue and claims expense remains narrow. The question for analysts is whether recent gains reflect sustained utilization control or timing effects in claims recognition.

Overhead Absorbs Most Gross Profit Gains

Based on AGL's reported figures, SG&A of roughly $54M to $88M per quarter consumes most of the gross profit generated, leaving operating margin at just 1.6% in the latest quarter despite the recovery in gross margin.

Operating income has moved more sharply than gross profit in both directions, indicating high fixed overhead relative to the earnings base. The latest quarter shows some positive operating leverage, but SG&A has not declined meaningfully as a share of revenue. Scaling efficiency will depend on whether overhead growth remains decoupled from membership growth over the coming periods.

EPS Swings Overstate Underlying Progress

According to reported results, AGL's diluted EPS moved from losses near -$11.50 in late 2025 to $1.97 in the latest quarter, a swing large enough that the share count and non-operating items likely deserve close scrutiny before drawing conclusions.

Net income has at times diverged meaningfully from operating income, and the magnitude of EPS swings relative to revenue suggests sensitivity to prior-period claim adjustments and possible tax effects. Stock-based compensation, while modest at $6M to $24M per quarter, remains a recurring cost that adds to dilution pressure. Investors should treat recent profitability as provisional until the consistency of net income with operating results is demonstrated over more periods.

Margin Recovery May Prove Temporary

The strongest challenge to the current narrative is that AGL's recent positive margins may reflect timing of medical cost recognition rather than durable improvement, given a history of sharp reversals across the ten-quarter window.

Negative revenue growth on a year-over-year basis, combined with persistent operating losses in much of the period, suggests the business has not yet proven it can scale profitably. Concentration risk in a few states and dependence on annual risk-adjustment outcomes could compress revenue abruptly if regulatory conditions shift. Analysts may wish to weight the trailing period heavily until several consecutive quarters of positive gross and operating margin are reported.

AGL — Frequently Asked Questions

Quick answers to the most common questions about buying AGL stock.

What was Agilon Health, Inc.'s (AGL) revenue in 2025?

For fiscal year 2025, Agilon Health, Inc. (AGL) reported total revenue of $5.93B. This represents a 646.8% increase compared to $794.4M in 2019.

Is Agilon Health, Inc. (AGL) profitable?

Agilon Health, Inc. (AGL) reported a net loss of $405.3M for the fiscal year ending 2025.

What is Agilon Health, Inc.'s operating profit margin?

Agilon Health, Inc. (AGL) reported an operating income of $-421.1M, resulting in an operating profit margin of -7.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Agilon Health, Inc.'s gross profit and gross margin?

Agilon Health, Inc. (AGL) generated $-188.6M in gross profit for the year, representing a gross profit margin of -3.2%. This demonstrates the company's core pricing power and production efficiency.